ATLANTA, GA - Morrisville, NC-based Furiex Pharmaceuticals Inc. says it has inked a loan agreement for $15 million to support research and development on three of its clinical stage compounds. The lenders are MidCap Financial MidCap FinancialLatest from The Business JournalsHawaii Medical Center files Chapter 11 bankruptcy — againCarepoint acquires ArTex infusion firmAtherotech acquired by Behrman CapitalFollow this company and Silcon Valley Bank.
(more…)

ATLANTA, GA - Cempra PharmaceuticalsCempra PharmaceuticalsLatest from The Business JournalsBlue Cross CEO, Quintiles president focus on costs at Health Care UDurham’s Clinpharm clocks growth as dosage specialistVC partner Kent joins Cempra boardFollow this company has raised $5 million in debt and warrants, according to U.S. Securities and Exchange Commission filings.
(more…)

ATLANTA, GA - Durham, NC-based venture capital fund Hatteras Venture Partners intends to announce today that it has raised $74 million for its fourth investment fund, putting it well more than halfway toward its $125 million goal.
(more…)

ATLANTA, GA - GeoVax Labs Inc.GeoVax Labs Inc.Latest from The Business JournalsGeoVax records 1,000 Q2 lossAIDS Research Alliance to test GeoVax HIV vaccine GeoVax trims first-quarter lossFollow this company has landed a $3.6 million Integrated Preclinical/Clinical AIDS Vaccine Development grant.
(more…)

SHREVEPORT, La. –Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today that it has closed on $4.5 million in a continuation of its Series A financing. Embera’s existing venture investors, Louisiana Ventures, L.P., Louisiana Fund I, and Themelios Ventures, as well as private investors, participated in the round. Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera’s clinical development programs for both smoking cessation and cocaine dependence.

(more…)

ATLANTA, GA - CryoLife Inc.CryoLife Inc.Latest from The Business JournalsCryoLife Q1 net income downCryoLife BioGlue heads to JapanCryoLife-Cardiogenesis merger changesFollow this company on Thursday reported a $3.5 million equity investment in ValveXchange Inc.ValveXchange Inc.Latest from The Business JournalsValveXchange wins Venture Showcase AwardWinners named in Bard Center business plan contestFollow this company, a private medical device company spun-off out of Cleveland Clinic to develop a lifetime heart valve replacement technology platform.
(more…)

ATLANTA, GA - Aldagen Inc.Aldagen Inc.Latest from The Business JournalsAldagen pulls .5 million IPOAldagen wins FDA’s OK to test stem-cell therapy for stroke Aldagen, still waiting on IPO, names new CEOFollow this company, a Durham-based biopharmaceutical company developing regenerative cell therapies, has raised $1.1 million in new funding.
(more…)

ATLANTA, GA - Mustard Tree Instruments, which makes drug testing equipment, has secured $4.8 million in first-round funding, the company announced Thursday.
(more…)

ATLANTA, GA - Regado BioSciencesRegado BioSciencesLatest from The Business JournalsFollow this company has raised another $26.1 million in a Series D funding round, according to a regulatory filing made this week with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange CommissionLatest from The Business JournalsXtreme Power completes .4M fundingSimon Property to give CEO 1 million shares to stayFlorida Bank Group gets million infusionFollow this company.

Durham-based venture capital group Aurora FundsAurora FundsLatest from The Business JournalsDurham biopharma Aldagen raises .1MFunder boosts Centice’s drug technologyDigitalsmiths buys top rival GotuitFollow this company is among the existing investors in Regado.
(more…)

DURHAM, N.C.–Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”), announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction. Upon closing, the combined company will be named Synageva BioPharma Corp., and will operate under the leadership of the Synageva management team with Sanj K. Patel serving as the President and Chief Executive Officer. In addition, the company’s board of directors will have representatives from both the existing Synageva and Trimeris boards. (more…)